# CYB5D2

## Overview
CYB5D2 is a gene that encodes the protein cytochrome b5 domain containing 2, also known as neuferricin. This protein is a member of the membrane-associated progesterone receptors (MAPRs) family and is characterized by the presence of a cytochrome b5 domain, which is involved in heme-binding and electron transfer processes. CYB5D2 is primarily associated with the endoplasmic reticulum membrane and plays a role in various cellular functions, including proliferation, differentiation, and survival. It is expressed in multiple tissues, notably in the central nervous system during embryonic development, and is implicated in promoting neuronal differentiation. The protein's involvement in cellular resistance to cytotoxicity and its potential interactions with other proteins suggest a complex role in cellular physiology. Additionally, CYB5D2 has been identified as a tumor suppressor in several cancers, highlighting its clinical significance and potential as a therapeutic target (Kimura2012Functions; Jiang2024CYB5D2; Xie2011CYB5D2).

## Function
CYB5D2, also known as neuferricin, is a member of the membrane-associated progesterone receptors (MAPRs) family and contains a cytochrome b5 domain. This protein is involved in various cellular processes, including proliferation, differentiation, and survival (Xie2011CYB5D2). CYB5D2 is associated with the endoplasmic reticulum (ER) membrane, as indicated by perinuclear staining patterns, and is involved in electron transfer processes within cells (Xie2011CYB5D2). It shares structural similarities with PGRMC1, particularly in the cytochrome b5 domain, which is involved in heme-binding and protection against DNA damage-induced toxicity (Xie2011CYB5D2).

CYB5D2 is expressed in the central nervous system during the mouse embryonic stage and in various tissues postnatally, including the brain, heart, adrenal gland, and kidney (Kimura2012Functions). It is involved in promoting neuronal differentiation but not astrocyte differentiation, indicating its role in nervous system development (Jiang2024CYB5D2). The protein's resistance to certain types of cytotoxicity, such as etoposide-induced cytotoxicity, requires both its transmembrane and cytochrome b5 domains (Xie2011CYB5D2). While the specific functions of CYB5D2 in healthy human cells remain unclear, its involvement in brain development and other physiological roles is suggested by its expression in multiple tissues (Kimura2012Functions).

## Clinical Significance
The CYB5D2 gene has been implicated in various cancers due to its role as a tumor suppressor. In hepatocellular carcinoma (HCC), CYB5D2 inhibits malignant progression by suppressing TGF-β expression and epithelial-mesenchymal transition (EMT). Its underexpression in liver cancer is associated with poor prognosis, suggesting its potential as a prognostic biomarker and therapeutic target (Jiang2024CYB5D2). In breast cancer, CYB5D2 is significantly downregulated, particularly in aggressive subtypes such as HER2-positive and triple-negative breast cancers. This downregulation is linked to decreased overall survival and is associated with mutations in genes like TP53 and RB1. The gene's expression is inversely related to cell proliferation, indicating its role in inhibiting tumor growth (Ojo2019Downregulation). In cervical cancer, CYB5D2 expression decreases as the disease progresses, correlating with advanced tumor stages. Its expression is positively associated with E-cadherin, an EMT marker, suggesting that CYB5D2 may inhibit EMT and serve as a prognostic marker for better relapse-free survival (Li2020Expression). These findings highlight CYB5D2's clinical significance in cancer progression and its potential utility in developing targeted therapies.

## Interactions
CYB5D2, also known as neuferricin, is a member of the membrane-associated progesterone receptors (MAPRs) family and contains a cytochrome b5-like heme/steroid-binding domain. This domain suggests potential interactions with other proteins, particularly in the context of heme-dependent processes. CYB5D2 can form heme-dependent homo- and/or heterodimers, indicating possible protein-protein interactions, although specific partners are not detailed (Ryu2017Membrane).

CYB5D2 is colocalized with POR (cytochrome P450 oxidoreductase) in the endoplasmic reticulum, suggesting potential interactions within the cellular environment (Ryu2017Membrane). Despite this colocalization, the specific physical interactions of CYB5D2 with other proteins or nucleic acids remain largely unexplored in the literature. The protein's role in stabilizing CYP51A1 and its potential involvement in CYP3A4 activation have been suggested, although the data is limited and not typically used for drug metabolism studies (Ryu2017Membrane).

In HeLa cells, CYB5D2 deficiency increases sensitivity to chemotherapeutic agents, but the low expression of drug-metabolizing CYPs in these cells makes the link between CYB5D2 and CYP function uncertain (Ryu2017Membrane). Overall, while CYB5D2 is implicated in various cellular processes, detailed interactions with other proteins or nucleic acids require further investigation.


## References


[1. (Ryu2017Membrane) Chang S. Ryu, Kathrin Klein, and Ulrich M. Zanger. Membrane associated progesterone receptors: promiscuous proteins with pleiotropic functions – focus on interactions with cytochromes p450. Frontiers in Pharmacology, March 2017. URL: http://dx.doi.org/10.3389/fphar.2017.00159, doi:10.3389/fphar.2017.00159. This article has 72 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphar.2017.00159)

2. (Jiang2024CYB5D2) CYB5D2 inhibits the malignant progression of hepatocellular carcinoma by inhibiting TGF-β expression and epithelial-mesenchymal transition. This article has 0 citations.

[3. (Li2020Expression) Dongxue Li, Bing Qiu, Xiaohang Chen, Liang Hu, Lijuan Wen, and Fengxiang Wei. Expression of cyb5d2 expression is associated with epithelial-mesenchymal transition and survival rates in patients with cervical cancer. Translational Cancer Research, 9(2):1185–1194, February 2020. URL: http://dx.doi.org/10.21037/tcr.2020.01.03, doi:10.21037/tcr.2020.01.03. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.21037/tcr.2020.01.03)

[4. (Xie2011CYB5D2) Yanyun Xie, Anthony Bruce, Lizhi He, Fengxiang Wei, Lijian Tao, and Damu Tang. Cyb5d2 enhances hela cells survival of etoposide-induced cytotoxicity. Biochemistry and Cell Biology, 89(3):341–350, June 2011. URL: http://dx.doi.org/10.1139/o11-004, doi:10.1139/o11-004. This article has 10 citations.](https://doi.org/10.1139/o11-004)

[5. (Kimura2012Functions) Ikuo Kimura, Yoshiaki Nakayama, Morichika Konishi, Kazuya Terasawa, Mitsuhiro Ohta, Nobuyuki Itoh, and Masafumi Fujimoto. Functions of mapr (membrane-associated progesterone receptor) family members as heme/steroid-binding proteins. Current Protein &amp; Peptide Science, 13(7):687–696, November 2012. URL: http://dx.doi.org/10.2174/138920312804142110, doi:10.2174/138920312804142110. This article has 51 citations.](https://doi.org/10.2174/138920312804142110)

[6. (Ojo2019Downregulation) Diane Ojo, David Rodriguez, Fengxiang Wei, Anita Bane, and Damu Tang. Downregulation of cyb5d2 is associated with breast cancer progression. Scientific Reports, April 2019. URL: http://dx.doi.org/10.1038/s41598-019-43006-y, doi:10.1038/s41598-019-43006-y. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-019-43006-y)